Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.37 |
| ▸ | DOT1L | Q8TEK3 | 1/20 | 0.32 |
| ▸ | DAPK1 | P53355 | 2/20 | 0.32 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.30 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.30 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.30 |
| ▸ | AHCY | P23526 | 2/20 | 0.30 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16707272 | 1.00 | SLC29A1 (0.37) | SLC29A1DOT1LDAPK1ADORA3ADORA2A | |
| SCHEMBL12936608 | 0.90 | SLC29A1 (0.37) | SLC29A1DOT1LDAPK1ADORA3ADORA2A | |
| SCHEMBL12515450 | 0.83 | TYMP (0.40) | SLC29A1DOT1LADORA1 | |
| SCHEMBL12803390 | 0.83 | TYMP (0.40) | SLC29A1DOT1LADORA1 | |
| SCHEMBL12936739 | 0.81 | TYMP (0.38) | SLC29A1ADORA1 | |
| SCHEMBL16707295 | 0.81 | TYMP (0.38) | SLC29A1ADORA1 | |
| SCHEMBL12803242 | 0.80 | TYMP (0.38) | SLC29A1ADORA1 | |
| SCHEMBL12936606 | 0.79 | SLC29A1 (0.53) | SLC29A1DOT1LDAPK1ADORA3ADORA2A | |
| SCHEMBL16707284 | 0.79 | SLC29A1 (0.53) | SLC29A1DOT1LDAPK1ADORA3ADORA2A | |
| SCHEMBL12936602 | 0.79 | SLC29A1 (0.53) | SLC29A1DOT1LDAPK1ADORA3ADORA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120252027-A1 | Method For Rapidly Evaluating Performance Of Short Interfering RNA With Novel Chemical Modifications | BANK OF AMERICA, N.A. | 2012-10-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120252027-A1 | Method For Rapidly Evaluating Performance Of Short Interfering RNA With Novel Chemical Modifications | NSUN2, NSUN3, SNRPE | SLC29A1 514/4885DOT1L 471/4885DAPK1 2849/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.